- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00747071
Safety and Validation of Efficacy of Oral Administration of the Food Additive Colostrum Derived Anti Clostridium Difficile Antibodies
August 27, 2012 updated by: Hadassah Medical Organization
This clinical study is designed to evaluate the safety and efficacy of oral administration of the food additive colostrum derived antibodies to Clostridium difficile for prevention of Clostridium difficile associated disease (CDAD).
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Jerusalem, Israel, 91120
- Hadassah Medical Organization
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18 or older
- Written informed consent
- At least 3 unformed or watery stools in each of the 2 previous 24 hour periods.
- Confirmed diagnosis of C. difficile associated diarrhea
Exclusion Criteria:
- Pregnant or breast feeding women
- Known allergy to milk or milk products
- Other etiology of diarrhea
- Active or Chronic conditions: IBD, short bowel syndrome, ischemic colitis Ileus
- Pseudomembranous colitis
- White blood count > 50,000
- Blood in stools
- Laxatives or motility drugs within 12 hours
- Inability to participate in adequate follow up
- Clinically unstable
- Investigator deems unsuitable
- Immune suppression (disease or treatment)
- GI surgery
- Past intestinal parasites
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Hospitalized patients with Clostridium difficile associated diarrhea.
|
Daily administration of Colostrum derived antibodies against C. difficile.
|
Experimental: 2
Close hospital contacts of each index case
|
Daily administration of Colostrum derived antibodies against C. difficile.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Recurrence of active Clostridium difficile associated diarrhea in index cases
Time Frame: 60 days
|
60 days
|
New cases of Clostridium difficile associated diarrhea in close hospital contacts.
Time Frame: 60 days
|
60 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease severity - duration, maximal intensity (number of stools) in index cases.
Time Frame: 60 days
|
60 days
|
Eradication of Clostridium difficile from stools
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (Anticipated)
November 1, 2012
Study Completion (Anticipated)
November 1, 2013
Study Registration Dates
First Submitted
September 3, 2008
First Submitted That Met QC Criteria
September 3, 2008
First Posted (Estimate)
September 4, 2008
Study Record Updates
Last Update Posted (Estimate)
August 28, 2012
Last Update Submitted That Met QC Criteria
August 27, 2012
Last Verified
June 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0180-08-HMO - CTIL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clostridium Difficile-Associated Diarrhea
-
Genzyme, a Sanofi CompanyCompletedClostridium Difficile-Associated Diarrhea | Antibiotic-associated Diarrhea | Clostridium Enterocolitis | Clostridium Difficile Diarrhea | Antibiotic-associated ColitisUnited States, Canada, United Kingdom, Puerto Rico
-
South Shore HospitalWithdrawnAntibiotic Associated Diarrhea | Clostridium Difficile Associated Diarrhea
-
Optimer Pharmaceuticals LLCCompletedClostridium Difficile-associated Diarrhea
-
Optimer Pharmaceuticals LLCCompleted
-
Astellas Pharma Europe B.V.Merck Sharp & Dohme LLCCompletedClostridium Difficile-associated Diarrhea (CDAD)United States, Belgium, Italy, Canada, France, Germany, Hungary, Poland, Romania, Spain
-
Merck Sharp & Dohme LLCCompletedClostridium Difficile Associated Diarrhea (CDAD)
-
Merck Sharp & Dohme LLCCompletedClostridium Difficile Associated Diarrhea (CDAD)
-
St. Vincent's East, Birmingham, AlabamaMaster Supplements, IncUnknownDevelopment of Clostridium Difficile Associated DiarrheaUnited States
-
Bio-K Plus International Inc.Sprim Advanced Life SciencesCompletedClostridium Difficile-Associated Diarrhea | Antibiotic-Associated Diarrhea
-
Bernhard Nocht Institute for Tropical MedicineGerman Federal Ministry of Education and ResearchTerminatedDiarrhea | Antibiotic-associated Diarrhea | Clostridium DifficileGermany
Clinical Trials on Colostrum
-
National Nutrition and Food Technology InstituteCompletedCritical IllnessIran, Islamic Republic of
-
Al-Mustafa University CollegeRecruitingDiabetes Mellitus, Type 2Iraq
-
National Nutrition and Food Technology InstituteCompletedCritical Illness | Multiple Organ Dysfunction Syndrome | Infection ComplicationIran, Islamic Republic of
-
Ain Shams UniversityCompletedFeeding; Difficult, Newborn | Necrotizing Enterocolitis of Newborn | Late Onset Neonatal SepsisEgypt
-
Centro de Investigación en Alimentación y Desarrollo...Completed
-
University of California, DavisCompletedChanges in the Oral MicrobiotaUnited States
-
Gadjah Mada UniversityCompletedPreterm | Very Low Birth Weight Baby | Trophic FeedingIndonesia
-
Milky Way Life Sciences LLCBeth Israel Deaconess Medical CenterRecruitingCeliac Disease | Gluten Sensitivity | Non-celiac Gluten SensitivityUnited States
-
Assiut UniversityNot yet recruiting
-
Sakarya UniversityUnknownOral Colostrum Administration in Very Low Birth Weight Premature InfantsTurkey